UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2004
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
000-29815
(Commission File Number)
Delaware | | 54-1655029 |
(State or other jurisdiction of incorporation) | | (I.R.S. Employer Identification No.) |
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(Address of principal executive offices and Zip Code)
(303) 426-6262
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 16, 2004, Allos Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the acquisition of an exclusive worldwide license from the University of Colorado Health Sciences Center, the University of Salford, and Cancer Research Technology to develop and commercialize a new chemotherapeutic agent known as RH1. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
99.1 | | Press Release, dated December 16, 2004, entitled “Allos Therapeutics Licenses New Cancer Compound”. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: December 16, 2004
| ALLOS THERAPEUTICS, INC. |
| | |
| By: | /s/ Michael E. Hart |
| | Michael E. Hart |
| Its: | President and Chief Executive Officer |
